CLOROX CO /DE/ 8K

Clorox furnished its Q4 and FY26 earnings and FY27 outlook, showing lower FY26 sales and EPS due to ERP-related shipment timing and GOJO acquisition costs while forecasting a return to growth in FY27 driven by the GOJO acquisition and lapping of ERP inventory impacts.

The Clorox Company filed a Form 8‑K to furnish its fourth quarter and fiscal year 2026 financial results and fiscal 2027 outlook, highlighting a 5% year-over-year decline in FY26 net sales to $6.72 billion and a 26% drop in diluted EPS to $4.81, largely due to the adverse comparison with prior-year ERP-related advance shipments, higher manufacturing and logistics costs, and transaction and integration expenses from its April 1, 2026 acquisition of GOJO Industries. The filing notes that GOJO (now operating as Clorox Purell and including the Purell brand) contributed to reported growth in Health and Wellness but also created short‑term gross margin pressure from inventory step‑up and other acquisition costs, while an ERP transition that drove incremental shipments in FY25 caused a significant drawdown in FY26 that reduced organic sales by about 8% and EPS by about $0.90. Clorox reports weaker segment adjusted EBIT across most businesses except International, lower operating cash flow (down 38% to $612 million, primarily due to a Glad venture termination payment), and elevated leverage following the GOJO acquisition and Glad joint venture buyout, but provides FY27 guidance calling for 13–14% net sales growth (including about 9.5 points from GOJO), organic sales growth of 3.5–4.5% supported by lapping the ERP inventory drawdown, and GAAP diluted EPS of $5.41–$5.71 and adjusted EPS of $5.70–$6.00, implying a return to earnings growth as integration progresses and the digital transformation spend subsides.

Filing Facts

CIK

21076

Ticker

-

Form

8K

Source Type

sec

Accession

0000021076-26-000028

Alert Tier

7